Nutriband Seeks to Revolutionize Transdermal Pain Management Through Innovative Abuse-Deterrent Technology
Nutriband is developing a groundbreaking transdermal drug delivery platform aimed at addressing pain management challenges in the wake of the opioid crisis, focusing on creating safer, more accessible opioid therapies.
Nutriband Inc. is positioning itself as a potential solution to the complex challenges surrounding pain management and opioid therapy. In a recent podcast interview, CEO Gareth Sheridan outlined the company's strategy to restore confidence in transdermal pain medication through its innovative AVERSA™ platform.
The pharmaceutical landscape has dramatically shifted since 2016, with the fentanyl patch market contracting from $4 billion to under $1 billion. This decline stems not from reduced patient need, but from increasing concerns about opioid abuse and safety. Nutriband aims to bridge this critical care gap by developing technologies that make opioid patches more difficult to manipulate for non-medical purposes.
The AVERSA™ platform represents a targeted approach to addressing the ongoing opioid crisis. By creating abuse-deterrent patches, Nutriband seeks to alleviate the stigma and liability concerns that have discouraged prescribers and healthcare providers from recommending transdermal opioid therapies.
This approach could potentially restore access to critical pain management treatments for patients who have been underserved by the current medical landscape. The technology offers a promising pathway to balance patient care with critical safety considerations, potentially reshaping how chronic pain is managed in clinical settings.